Trials / Not Yet Recruiting
Not Yet RecruitingNCT07410169
Efficacy and Safety of Hyperbaric Oxygen Therapy in Improving Nab-paclitaxel-Induced Peripheral Neuropathy
Efficacy and Safety of Hyperbaric Oxygen Therapy in Improving Nab-paclitaxel-Induced Peripheral Neuropathy: A Randomized Clinical Trial
- Status
- Not Yet Recruiting
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 160 (estimated)
- Sponsor
- Guangdong Provincial People's Hospital · Academic / Other
- Sex
- Female
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this research is to assess whether hyperbaric oxygen therapy can alleviate the symptoms of Nab-paclitaxel-induced peripheral neuropathy and improve patient-reported quality of life.
Conditions
- Breast Cancer
- CIPN - Chemotherapy-Induced Peripheral Neuropathy
- Paclitaxel-induced Peripheral Neuropathy
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Hyperbaric oxygen treatment | Patients who meet the inclusion criteria will be enrolled and given hyperbaric oxygen intervention, one per day for 90-120 minutes, for a total of 20-30 hyperbaric oxygen treatments (100% oxygen at a pressure of 2.0 ATA) |
| OTHER | Standard Care (in control arm) | Standard care |
Timeline
- Start date
- 2026-01-31
- Primary completion
- 2027-12-31
- Completion
- 2027-12-31
- First posted
- 2026-02-13
- Last updated
- 2026-02-13
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07410169. Inclusion in this directory is not an endorsement.